Clinical trial NCT01768026: Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa
Official title: A Prospective, Longitudinal Assessment of Disease Severity in Subjects With Dystrophic Epidermolysis Bullosa (DEB)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Dystrophic Epidermolysis Bullosa
Keywords: Dystrophic Epidermolysis Bullosa
Type VII Collagen
QOL Evaluation in Epidermolysis Bullosa
Instrument for Scoring Clinical Outcomes for Research of Epidermolysis Bullosa
Birmingham Epidermolysis Bullosa Severity Score
Lead sponsor: Lotus Tissue Repair, Inc.
Sponsor class: INDUSTRY
First posted: 2013-01-15
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be selected from clinical sites with interdisciplinary clinics for Dystrophic Epidermolysis Bullosa

Brief summary: The objective of this study is to characterize the extent and severity of disease in subjects with DEB and the progression of disease over a timeframe relevant to interventional studies. The data from this study will be used to inform the study design and address statistical considerations of future treatment protocols.

Detailed description: This is a prospective, multicenter, multinational, longitudinal assessment of disease severity in subjects with DEB. Subjects with either dominant or recessive DEB (dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB), respectively) will be assessed four times over a one year period: upon enrollment, and at 1 to 2 weeks and 6 and 12 months after enrollment. All subjects with either DDEB or RDEB that meet the study entry criteria will be offered participation in the study, provided they can be accommodated within the anticipated study timeline. In addition to their usual clinic assessment, subjects will have a quantitative evaluation of skin involvement and will be asked to fill out questionnaires that measure among other things disease severity, QOL, pain, pruritus, and medical and family histories.

Eligibility criteria: Eligibility Criteria

* Subjects of any age (newborns included) may participate
* Subjects over 18 years of age and parent(s)/legal guardian(s) of subjects \<18 years of age must provide written informed consent prior to participating in the study and informed assent will be obtained from minors at least 7 years of age
* Subjects must have a documented diagnosis of DEB based on clinical presentation and either skin biopsy results showing an absence or reduction in C7 or anchoring fibrils or genetic analysis showing a mutation in collagen, type VII, alpha 1 (Col7A1); alternatively, subjects must have a clinical diagnosis of DEB and a documented diagnosis of DEB (as above) in a first degree relative
* No experimental systemic therapy for DEB including, but not limited to, bone marrow transplantation, systemic immune suppression, or experimental therapies that involve live cells which have the potential for systemic spread such as gene transfer, stem cell infusions or other cell type injections

Primary outcomes:
measure: Characterize the progression of disease severity in subjects with DEB over 6 - 12 months.
timeFrame: One year period
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Lotus Tissue Repair, Inc.
name: Hal Landy, MD
role: STUDY_DIRECTOR
References: